The consistency of findings from these and other analyses,14 enables simple clinical practice guidelines for patients with CKD.30,31 These results are particularly important for patients with CKD without diabetes who have been less well studied in the completed RAS inhibitor32–34 and mineralocorticoid receptor trials,35 and for whom serious side effects of SGLT2 inhibitors appear uncommon.5 SGLT2 inhibitors should become part of a standard of care for many patients with CKD. This evidence concerns the gene NR3C2 and chronic kidney disease.